FDA Approves Moderna's mRNA Flu Vaccine for Adults 50 and Older
The US Food and Drug Administration has approved Moderna's mRNA-based influenza vaccine, mFLUSIVA, for use in adults aged 50 and above. The approval marks a significant milestone for mRNA vaccine technology, extending its application beyond COVID-19 into seasonal flu prevention. Moderna's flu shot uses the same mRNA platform that underpinned its widely used COVID-19 vaccines. The approval came after a review process described as turbulent, though the vaccine ultimately cleared regulatory requirements.









